Treatment should be stopped if nonarteritic anterior ischemic optic neuropathy, which can cause vision loss, is diagnosed.

The aim is to “activate these guidelines in a way that they become more actionable for clinicians,” Harlan Krumholz says.

The lack of effect shouldn’t detract from MINT, which showed a strong trend toward benefit with liberal blood transfusion.